Eli Lilly (LLY) has signed a global research and licensing deal with South Korea-based Rznomics to develop RNA-editing therapies, Rznomics said in a statement Thursday.
The partnership will use Rznomics' proprietary ribozyme platform to target treatments for sensorineural hearing loss.
Rznomics will lead early-stage research, while Lilly will handle later-stage development and global commercialization.
The total deal value could exceed $1.3 billion if all options are exercised, along with future royalties on sales. The upfront payment was not disclosed, according to the company.
Shares of Eli Lilly were up nearly 2% in recent trading.
Price: 729.33, Change: +13.77, Percent Change: +1.92
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。